Danielle Bucco

Articles

Expert Shares Insight on Biomarker Development in RCC

February 14th 2018

Kerstin Junker, MD, PhD, discusses the need to identify prognostic biomarkers for patients with RCC.

Sequencing Questions Remain in Prostate Cancer Paradigm

February 13th 2018

Christopher Sweeney, MBBS, discusses the role of abiraterone for patients with hormone-sensitive prostate cancer, and what physicians should consider when choosing between abiraterone and docetaxel.

PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment

February 10th 2018

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

February 10th 2018

David O'Malley, MD, discusses the excitement surrounding PARP inhibitors for patients with ovarian cancer.

Immunotherapy Combinations Slated to Pave the Way in Ovarian Cancer Treatment

February 9th 2018

Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.

Rhabdomyosarcoma Cell Origin Affects Treatment and Survival of Pediatric Patients

February 9th 2018

Mark E. Hatley, MD, discusses the research of endothelial progenitor cells in pediatric patients with rhabdomyosarcoma and how it can lead to thorough analyses of the tumor cells.

Higher Distress Scores Linked With Lower Survival in Myeloma

February 8th 2018

John Richter, MD, discusses the findings form the self-reported symptom and psychological survey in patients with multiple myeloma.

Expert Discusses Letermovir Approval for CMV Prophylaxis Post-Transplantation

February 7th 2018

Miguel Perales, MD, discusses the impact of the FDA approval of letermovir for patients with CMV prophylaxis following transplantation.

Kulke Sheds Light on Emerging Agents for Neuroendocrine Tumors

February 6th 2018

Matthew Kulke, MD, discusses the evolving treatment paradigm for patients with neuroendocrine tumors.

Tucatinib Combo Explored in HER2-Positive Breast Cancer

February 1st 2018

Rashmi K. Murthy, MD, MBE, discusses the role of tucatinib in CNS metastases for patients with HER2-positive breast cancer.

Vaccine Therapy Shows Promise in Cervical Cancer

February 1st 2018

Sharad Ghamande, MD, discusses the findings from GOG/NRG-0265, as well as the impact of vaccines for patients with cervical cancer.

Immunotherapy Active in Advanced GISTs

January 31st 2018

Arun S. Singh, MD, discusses the developing role of immunotherapy in patients with GISTs, particularly the randomized phase II trial investigating nivolumab as a single agent and in combination with ipilimumab.

Screening Continues to Evolve in Prostate Cancer

January 30th 2018

Marc A. Bjurlin, DO, discusses ongoing efforts to optimize prostate cancer screening.

Liso-Cel Highly Active in Relapsed/Refractory DLBCL

January 30th 2018

David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.

Novel Combinations Continue to Advance Melanoma Field

January 29th 2018

Mario Sznol, MD, discusses overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.

Novel Agents Advance Field of AML

January 24th 2018

Gabriel Mannis, MD, discusses novel therapies shifting the treatment paradigm for patients with AML.

10-Year PROTECT Data Underscore Significance of Precision Medicine in Prostate Cancer

January 22nd 2018

Malcolm Mason, MD, discusses the significance of the 10-year follow-up of the PROTECT study for patients with prostate cancer and what it means for the field going forward.

Classifying NETs Versus NECs in Gastrointestinal Cancer

January 18th 2018

Jennifer Eads, MD, discusses the classification of NETs versus NECs in gastrointestinal cancer.

Emerging Therapies Generate Excitement in Myeloma

January 17th 2018

Thomas G. Martin, MD, discusses emerging advancements in the treatment landscape of multiple myeloma.

Bunn Expands on Significance of Atezolizumab/Bevacizumab Regimen in NSCLC

January 16th 2018

Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.